ClinicalTrials.gg
CompletedNCT04657198Updated Jun 29, 2022Results posted

Extension Study to Evaluate the Safety and Immunogenicity of a Revaccination Dose of the RSVPreF3 OA Investigational Vaccine in Adults 60 Years and Older Who Participated in the RSV OA=ADJ-002 Study

A Phase 2 interventional study of RSVPreF3 OA investigational vaccine (GSK3844766A) in Respiratory Syncytial Virus Infections, sponsored by GlaxoSmithKline. Completed at 10 sites in 2 countries. Open to participants aged 60 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-06-29.

Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
126
Allocation
Non-randomized
Ages
60 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 40 studies in Respiratory Syncytial Virus Infections by GlaxoSmithKline — 1 open to participants now, 5 under way, 3 of them phase 3. Respiratory Syncytial Virus Infections · GlaxoSmithKline.

Enrollment
33rd of 40
126 · median 642
Started
2020
with 1 other
Phase 2
9 of 40
none open now
Registered
16th of 40
by date

Among the 40 studies in Respiratory Syncytial Virus Infections by GlaxoSmithKline, this one is the 33rd largest by enrollment, is one of 2 that started in 2020, is one of 9 in phase 2, and was the 16th registered.

Respiratory Syncytial Virus Infections

306 studies on the registry are indexed under Respiratory Syncytial Virus Infections; 49 are open to participants now.

Browse Respiratory Syncytial Virus Infections studies →

Open to participants now

1 of the 40 studies in Respiratory Syncytial Virus Infections by GlaxoSmithKline is open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 29 Respiratory Syncytial Virus Infections studies recruiting now, 14 (48%) set no upper age limit and 11 (38%) stop at 75 or younger; 13 take children under 18; 8 take healthy volunteers.

This study: 60 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies in Respiratory Syncytial Virus Infections by GlaxoSmithKline, or all of them as a file.
02

Study summary

Nine different formulations of the RSVPreF3 OA investigational vaccine were tested in the parent study (NCT03814590). Based on safety and immunogenicity data from the parent study, RSVPreF3 OA investigational vaccine will be evaluated in further clinical research. Participants in selected groups will be invited to participate in this extension study. All participants who will be enrolled in the current extension study will receive the RSV investigational vaccine approximately 18 months after they received their respective dose-2 in the parent study.

03

Conditions studied

  • Respiratory Syncytial Virus Infections

Keywords

  • Respiratory syncytial virus
  • Vaccine
  • Safety
  • Immunogenicity
04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female participants, who received 2 doses of RSVPreF3 OA vaccine and formulations with matched adjuvant in part B of the parent study RSV OA=ADJ-002: recombinant RSVPreF3 antigen doses of low, medium and high strengths with adjuvant.
  • Participants who, in the opinion of the investigator, can and will comply with the requirements of the protocol (e.g. completion of the diary cards, return for the follow-up visit, be available for contact)
  • Written obtained from the participant prior to performance of any study specific procedure.

Exclusion criteria

Exclusion Criteria:

Medical conditions

  • Significant underlying illness or administered therapy that in the opinion of the investigator would be expected to prevent participation in the study.
  • Any confirmed or suspected or immunodeficient condition based on information on concomitant medication/vaccination collected prior to the study start and physical examination.
  • Serious or unstable chronic illness that developed during or after the parent study. Patients with chronic stable medical conditions with or without specific treatment, such as diabetes, hypertension or cardiac disease, are allowed to participate in this study if considered by the investigator as clinically stable.
  • Recurrent or un-controlled neurological disorders or seizures that developed during or after the parent study. Participants with medically-controlled active or chronic neurological diseases can be enrolled in the study as per investigator assessment, provided that their condition will allow them to comply with the requirements of the protocol.
  • Significant underlying illness that developed during or after the parent study, that in the opinion of the investigator would be expected to prevent completion of the study.
  • Lymphoproliferative disorder and developed during or after the parent study.
  • Any medical condition that developed during or after the parent study, that in the judgment of the investigator would make intramuscular injection unsafe.
  • Previous vaccination with RSV vaccine, other than the one in the parent study.

Prior/Concomitant therapy

  • Use of any or non-registered product (drug, vaccine or medical device) other than the study vaccine during the period beginning 30 days before the dose of study vaccine, or planned use during the study period.
  • Planned or actual administration of a vaccine not foreseen by the study protocol in the period starting 30 days before and ending 30 days after the dose of study vaccine administration, with the exception of inactivated, split virion and subunit influenza vaccines which can be administered up to 14 days before or from 30 days after the study vaccination.
  • Administration of long-acting immune-modifying drugs or planned administration at any time during the study period.
  • Administration of immunoglobulins and/or any blood products or plasma derivatives during the period starting 90 days before the dose of study vaccine or planned administration during the study period.
  • Chronic administration (defined as more than 14 consecutive days in total) of immunosuppressants or other immune-modifying drugs during the period starting 90 days prior to the vaccine dose or planned administration during the study period. For , this will mean prednisone ≥20 mg/day, or equivalent. Inhaled and topical steroids are allowed.
  • Confirmed use or anticipated use of immunosuppressive/cytotoxic therapy.

Prior/Concurrent clinical study experience

  • Concurrently participating in another clinical study, at any time during the study period, in which the participant has been or will be exposed to an investigational or a non-investigational vaccine/product.

Other exclusions

  • Bedridden participants.
  • Planned move to a location that will prohibit participating in the trial.
  • History of chronic alcohol consumption and/or drug abuse that developed during or after the parent study as deemed by the investigator to render the potential participant unable/unlikely to provide accurate safety reports or comply with study procedures.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
126 participants (actual)

Study arms

  • Experimental
    Group High Dose_Adjuvanted

    Participants in one of the high dose adjuvanted groups in part B of the parent study RSV OA=ADJ-002: Group High Dose Adjuvanted will receive one revaccination dose of the RSVPreF3 OA investigational vaccine in the current study by intramuscular (IM) injection in the non-dominant arm.

    Biological: RSVPreF3 OA investigational vaccine (GSK3844766A)

  • Experimental
    Group Medium Dose_Adjuvanted

    Participants in one of the medium dose adjuvanted groups in part B of the parent study RSV OA=ADJ-002: Group Medium Dose Adjuvanted will receive one revaccination dose of the RSVPreF3 OA investigational vaccine in the current study by IM injection in the non-dominant arm.

    Biological: RSVPreF3 OA investigational vaccine (GSK3844766A)

  • Experimental
    Group Low Dose_Adjuvanted

    Participants in one of the low dose adjuvanted groups in part B of the parent study RSV OA=ADJ-002: Group Low Dose Adjuvanted will receive one revaccination dose of the RSVPreF3 OA investigational vaccine in the current study by IM injection in the non-dominant arm.

    Biological: RSVPreF3 OA investigational vaccine (GSK3844766A)

Interventions

  • BiologicalRSVPreF3 OA investigational vaccine (GSK3844766A)

    RSVPreF3 OA investigational vaccine administered intramuscularly in the deltoid region of the non-dominant arm, at Day 1 (18 months post-Dose 2 in the RSV OA=ADJ-002 parent study).

06

What researchers measure

Primary outcomes

  1. Number of Participants With Any Solicited Administration Site Adverse Events (AEs)

    Assessed solicited administration site AEs are erythema, pain and swelling. Any pain is defined as any pain regardless of intensity grade. Any injection site erythema/swelling is scored with a diameter larger than (\>) 20 millimeters (mm).

    Time frame: During the 4-day follow-up period post-vaccination (i.e. on the day of vaccination [Day 1] and 3 subsequent days)

  2. Number of Participants With Any Solicited Systemic AEs

    Assessed solicited systemic AE is fever (any temperature greater than or equal to 38.0 °C - the preferred location for measuring temperature being the oral cavity). Any is defined as occurrence of the symptom regardless of intensity grade or relation to study.

    Time frame: During the 4-day follow-up period post-vaccination (i.e. on the day of vaccination [Day 1] and 3 subsequent days)

  3. Number of Participants With Any Unsolicited AEs

    An unsolicited AE is any AE reported in addition to those solicited during the clinical study. Also, any 'solicited' symptom with onset outside the specified period of follow-up for solicited symptoms is reported as an unsolicited AE. Any is defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to study vaccination.

    Time frame: During the 30-day follow-up period post-vaccination (i.e., on the day of vaccination [Day 1] and 29 subsequent days)

  4. Number of Participants With Any Serious Adverse Events (SAEs) up to 30 Days Post-vaccination

    An SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization or results in disability/incapacity. Any is defined as any occurrence of SAE regardless of intensity grade or relation to study vaccination.

    Time frame: From Day 1 up to 30 days post-vaccination (Day 31)

  5. Number of Participants With Any Potential Immune-mediated Diseases (pIMDs) up to 30 Days Post-vaccination

    pIMDs are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune etiology. Any is defined as the occurrence of any pIMD regardless of intensity grade or relation to study vaccination.

    Time frame: From Day 1 up to 30 days post-vaccination (Day 31)

  6. Humoral Immune Response in Terms of Neutralizing Antibody Titers Against Respiratory Syncytial Virus (RSV)-Serotype A

    Serological assays for the determination of functional antibodies against RSV-A are performed by neutralization assay. Anti RSV-A neutralizing antibody titers are given as Geometric Mean Titers (GMTs) and expressed as Estimated Dose: serum dilution giving a 60% reduction of the signal compared to a control without serum (ED60).

    Time frame: At 30 days post-vaccination (Day 31)

  7. Humoral Immune Response in Terms of Neutralizing Antibody Titers Against RSV-serotype B

    Serological assays for the determination of functional antibodies against RSV-B are performed by neutralization assay. Anti RSV-B neutralizing antibody titers are given as GMTs and expressed as ED60.

    Time frame: At 30 days post-vaccination (Day 31)

Secondary outcomes

  1. Humoral Immune Response in Terms of RSVPreF3-specific Immunoglobulin G (IgG) Antibody Concentrations

    The detection and the quantification of total IgG antibodies directed against RSVPreF3 in human serum samples were based on an indirect Enzyme-Linked Immunosorbent Assay (ELISA). Anti RSVPreF3 antibody concentration is given in geometric mean concentration (GMC) and is expressed in ELISA Laboratory Units per milliliter (ELU/mL).

    Time frame: At 30 days post-vaccination (Day 31)

  2. Frequency of RSVPreF3-specific Cluster of Differentiation 4+ (CD4+) T-cells Identified as Expressing at Least Two Markers

    Among markers expressed are interleukin-2 (IL2), cluster of 40 ligand (CD40L), tumour necrosis factor alpha (TNF α) and interferon gamma (IFN γ), in vitro upon stimulation with RSVPreF3 peptide preparations.

    Time frame: At 30 days post-vaccination (Day 31)

  3. Number of Participants With Any SAEs, up the End of Follow-up Study Period (Month 6)

    An SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization or results in disability/incapacity.

    Time frame: From Day 1 up to the end of follow-up period (Month 6)

  4. Number of Participants Reporting pIMDs up to the End of Follow-up Study Period (Month 6)

    pIMDs are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune etiology.

    Time frame: From Day 1 up to the end of follow-up period (Month 6)

07

Results

Posted Jun 29, 2022

Participant flow

From a total of 126 participants enrolled in this study, 4 participants were withdrawn before vaccination. 122 participants received the study vaccination.

Participant flow — Overall Study
MilestoneHigh Dose_AS01E GroupLow Dose_AS01E GroupMedium Dose_AS01E Group
Started403943
Completed393943
Not completed100
Withdrew: Consent withdrawal, not due to a (s)ae100

Outcome measures

PrimaryNumber of Participants With Any Solicited Administration Site Adverse Events (AEs)

Assessed solicited administration site AEs are erythema, pain and swelling. Any pain is defined as any pain regardless of intensity grade. Any injection site erythema/swelling is scored with a diameter larger than (\>) 20 millimeters (mm).

Time frame:
During the 4-day follow-up period post-vaccination (i.e. on the day of vaccination [Day 1] and 3 subsequent days)
Reported as:
Count of participants · Participants
Number of Participants With Any Solicited Administration Site Adverse Events (AEs)
ParticipantsHigh Dose_AS01E GroupLow Dose_AS01E GroupMedium Dose_AS01E Group
Any erythema165
Any pain212326
Any swelling024
PrimaryNumber of Participants With Any Solicited Systemic AEs

Assessed solicited systemic AE is fever (any temperature greater than or equal to 38.0 °C - the preferred location for measuring temperature being the oral cavity). Any is defined as occurrence of the symptom regardless of intensity grade or relation to study.

Time frame:
During the 4-day follow-up period post-vaccination (i.e. on the day of vaccination [Day 1] and 3 subsequent days)
Reported as:
Count of participants · Participants
Number of Participants With Any Solicited Systemic AEs
ParticipantsHigh Dose_AS01E GroupLow Dose_AS01E GroupMedium Dose_AS01E Group
Number of Participants With Any Solicited Systemic AEs114
PrimaryNumber of Participants With Any Unsolicited AEs

An unsolicited AE is any AE reported in addition to those solicited during the clinical study. Also, any 'solicited' symptom with onset outside the specified period of follow-up for solicited symptoms is reported as an unsolicited AE. Any is defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to study vaccination.

Time frame:
During the 30-day follow-up period post-vaccination (i.e., on the day of vaccination [Day 1] and 29 subsequent days)
Reported as:
Count of participants · Participants
Number of Participants With Any Unsolicited AEs
ParticipantsHigh Dose_AS01E GroupLow Dose_AS01E GroupMedium Dose_AS01E Group
Number of Participants With Any Unsolicited AEs51112
PrimaryNumber of Participants With Any Serious Adverse Events (SAEs) up to 30 Days Post-vaccination

An SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization or results in disability/incapacity. Any is defined as any occurrence of SAE regardless of intensity grade or relation to study vaccination.

Time frame:
From Day 1 up to 30 days post-vaccination (Day 31)
Reported as:
Count of participants · Participants
Number of Participants With Any Serious Adverse Events (SAEs) up to 30 Days Post-vaccination
ParticipantsHigh Dose_AS01E GroupLow Dose_AS01E GroupMedium Dose_AS01E Group
Number of Participants With Any Serious Adverse Events (SAEs) up to 30 Days Post-vaccination000
PrimaryNumber of Participants With Any Potential Immune-mediated Diseases (pIMDs) up to 30 Days Post-vaccination

pIMDs are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune etiology. Any is defined as the occurrence of any pIMD regardless of intensity grade or relation to study vaccination.

Time frame:
From Day 1 up to 30 days post-vaccination (Day 31)
Reported as:
Count of participants · Participants
Number of Participants With Any Potential Immune-mediated Diseases (pIMDs) up to 30 Days Post-vaccination
ParticipantsHigh Dose_AS01E GroupLow Dose_AS01E GroupMedium Dose_AS01E Group
Number of Participants With Any Potential Immune-mediated Diseases (pIMDs) up to 30 Days Post-vaccination000
PrimaryHumoral Immune Response in Terms of Neutralizing Antibody Titers Against Respiratory Syncytial Virus (RSV)-Serotype A

Serological assays for the determination of functional antibodies against RSV-A are performed by neutralization assay. Anti RSV-A neutralizing antibody titers are given as Geometric Mean Titers (GMTs) and expressed as Estimated Dose: serum dilution giving a 60% reduction of the signal compared to a control without serum (ED60).

Time frame:
At 30 days post-vaccination (Day 31)
Reported as:
Geometric mean · Titers
Humoral Immune Response in Terms of Neutralizing Antibody Titers Against Respiratory Syncytial Virus (RSV)-Serotype A
TitersHigh Dose_AS01E Group
Humoral Immune Response in Terms of Neutralizing Antibody Titers Against Respiratory Syncytial Virus (RSV)-Serotype A4394.9 (3191.3 to 6052.5)
PrimaryHumoral Immune Response in Terms of Neutralizing Antibody Titers Against RSV-serotype B

Serological assays for the determination of functional antibodies against RSV-B are performed by neutralization assay. Anti RSV-B neutralizing antibody titers are given as GMTs and expressed as ED60.

Time frame:
At 30 days post-vaccination (Day 31)
Reported as:
Geometric mean · Titers
Humoral Immune Response in Terms of Neutralizing Antibody Titers Against RSV-serotype B
TitersHigh Dose_AS01E Group
Humoral Immune Response in Terms of Neutralizing Antibody Titers Against RSV-serotype B6094.3 (4476.8 to 8296.4)
SecondaryHumoral Immune Response in Terms of RSVPreF3-specific Immunoglobulin G (IgG) Antibody Concentrations

The detection and the quantification of total IgG antibodies directed against RSVPreF3 in human serum samples were based on an indirect Enzyme-Linked Immunosorbent Assay (ELISA). Anti RSVPreF3 antibody concentration is given in geometric mean concentration (GMC) and is expressed in ELISA Laboratory Units per milliliter (ELU/mL).

Time frame:
At 30 days post-vaccination (Day 31)
Reported as:
Geometric mean · ELU/mL
Humoral Immune Response in Terms of RSVPreF3-specific Immunoglobulin G (IgG) Antibody Concentrations
ELU/mLHigh Dose_AS01E Group
Humoral Immune Response in Terms of RSVPreF3-specific Immunoglobulin G (IgG) Antibody Concentrations46276.5 (36821.3 to 58159.6)
SecondaryFrequency of RSVPreF3-specific Cluster of Differentiation 4+ (CD4+) T-cells Identified as Expressing at Least Two Markers

Among markers expressed are interleukin-2 (IL2), cluster of 40 ligand (CD40L), tumour necrosis factor alpha (TNF α) and interferon gamma (IFN γ), in vitro upon stimulation with RSVPreF3 peptide preparations.

Time frame:
At 30 days post-vaccination (Day 31)
Reported as:
Median · cells per million CD4+ T Cells
Frequency of RSVPreF3-specific Cluster of Differentiation 4+ (CD4+) T-cells Identified as Expressing at Least Two Markers
cells per million CD4+ T CellsHigh Dose_AS01E Group
Frequency of RSVPreF3-specific Cluster of Differentiation 4+ (CD4+) T-cells Identified as Expressing at Least Two Markers1601 (1174 to 2541)
SecondaryNumber of Participants With Any SAEs, up the End of Follow-up Study Period (Month 6)

An SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization or results in disability/incapacity.

Time frame:
From Day 1 up to the end of follow-up period (Month 6)
Reported as:
Count of participants · Participants
Number of Participants With Any SAEs, up the End of Follow-up Study Period (Month 6)
ParticipantsHigh Dose_AS01E GroupLow Dose_AS01E GroupMedium Dose_AS01E Group
Number of Participants With Any SAEs, up the End of Follow-up Study Period (Month 6)112
SecondaryNumber of Participants Reporting pIMDs up to the End of Follow-up Study Period (Month 6)

pIMDs are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune etiology.

Time frame:
From Day 1 up to the end of follow-up period (Month 6)
Reported as:
Count of participants · Participants
Number of Participants Reporting pIMDs up to the End of Follow-up Study Period (Month 6)
ParticipantsHigh Dose_AS01E GroupLow Dose_AS01E GroupMedium Dose_AS01E Group
Number of Participants Reporting pIMDs up to the End of Follow-up Study Period (Month 6)000

Adverse events

Collected over Solicited AEs were collected during the 4-day follow-up period after vaccination. Unsolicited AEs were collected during the 30-day follow-up period after vaccination. SAEs and pIMDs were collected throughout the study period (from Day 1 to Month 6).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
High Dose_AS01E Group0/40 (0%)1/40 (2.5%)22/40 (55%)
Low Dose_AS01E Group0/39 (0%)1/39 (2.6%)25/39 (64.1%)
Medium Dose_AS01E Group0/43 (0%)2/43 (4.7%)29/43 (67.4%)
Most frequent serious events
Most frequent serious events
EventHigh Dose_AS01E GroupLow Dose_AS01E GroupMedium Dose_AS01E Group
DiverticulitisInfections and infestations0/401/390/43
Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/400/390/43
Limb traumatic amputationInjury, poisoning and procedural complications0/400/391/43
Benign prostatic hyperplasiaReproductive system and breast disorders0/400/391/43
Most frequent other events
Showing 10 of 36
Most frequent other events
EventHigh Dose_AS01E GroupLow Dose_AS01E GroupMedium Dose_AS01E Group
Injection site painGeneral disorders21/4023/3926/43
Injection site erythemaGeneral disorders1/406/395/43
HeadacheNervous system disorders1/404/391/43
Injection site swellingGeneral disorders0/402/394/43
PyrexiaGeneral disorders1/401/394/43
FatigueGeneral disorders1/401/393/43
ChillsGeneral disorders0/402/392/43
Influenza like illnessGeneral disorders0/402/392/43
MalaiseGeneral disorders0/402/391/43
Axillary painGeneral disorders0/401/390/43

Baseline characteristics

Age, Continuous
Age, Continuous(Years)High Dose_AS01E GroupLow Dose_AS01E GroupMedium Dose_AS01E GroupTotal
Mean68.3 ± 5.469.1 ± 5.366.6 ± 5.668.0 ± 5.5
Sex: Female, Male
Sex: Female, Male(Participants)High Dose_AS01E GroupLow Dose_AS01E GroupMedium Dose_AS01E GroupTotal
Female27212472
Male13181950
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)High Dose_AS01E GroupLow Dose_AS01E GroupMedium Dose_AS01E GroupTotal
American Indian Or Alaska Native1001
Black Or African American1214
White383742117
08

Study locations

10 sites
  • GSK Investigational Site
    Lenexa, Kansas 66219, United States
  • GSK Investigational Site
    Elkridge, Maryland 21075, United States
  • GSK Investigational Site
    Omaha, Nebraska 68134, United States
  • GSK Investigational Site
    Rochester, New York 14609, United States
  • GSK Investigational Site
    Hickory, North Carolina 28601, United States
  • GSK Investigational Site
    Mount Pleasant, South Carolina 29464, United States
  • GSK Investigational Site
    San Antonio, Texas 78229, United States
  • GSK Investigational Site
    Gent, 9000, Belgium
  • GSK Investigational Site
    Leuven, 3000, Belgium
  • GSK Investigational Site
    Wilrijk, 2610, Belgium
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.

Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2020 to primary completion in Jun 2021, 5 months.

Results were first posted in Jun 2022, 1 year after primary completion.

Of 32 industry-sponsored phase 2 interventional studies under Respiratory Syncytial Virus Infections, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 27. This study's 5 months is below that.

Counting every sponsor, half of 37 studies reached it within 11 months; a quarter within 5 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 1, 2020
First posted
Dec 8, 2020
StartActual
Dec 9, 2020
Primary completionActual
Jun 3, 2021
CompletionActual
Oct 25, 2021
Results first posted
Jun 29, 2022
Last update
Jun 29, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 29, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04657198
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Dec 8, 2020
Start date
Dec 9, 2020
Primary completion
Jun 3, 2021
Completion
Oct 25, 2021
Results posted
Jun 29, 2022
Last update
Jun 29, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion